Intracerebral hemorrhage associated with sildenafil use: a case report.
Alpsan
M H
MH
Bebek
N
N
Ciftci
F D
FD
Coban
O
O
Bahar
S
S
Tuncay
R
R
D002536:Cerebral Arteries / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D006152:Cyclic GMP / Q000378:metabolism; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D020772:Internal Capsule / Q000098:blood supply / Q000000981:diagnostic imaging / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010291:Paresis / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000473:pathology; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D010879:Piperazines / Q000009:adverse effects*; D011687:Purines / Q000009:adverse effects; D020127:Recovery of Function; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000009:adverse effects*; D013788:Thalamus / Q000098:blood supply / Q000000981:diagnostic imaging / Q000473:pathology; D014057:Tomography, X-Ray Computed; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000009:adverse effects*
D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006152:Cyclic GMP